PharmaTech

JUNE 9, 2025

Similarly, while some nanoscale delivery systems can exhibit prolonged lifetimes in the bloodstream, others have short circulation times or can be viewed as foreign materials by the immune system and rapidly cleared. These uncertainties and complexity of nanoscale drug delivery systems often lead to regulatory challenges.

Dosage 52

Dosage Drug Development Immunity Immunization 52

Pharmacy Times

JUNE 19, 2025

SHOW MORE With robust pipelines, cell therapy remains the major driver for drug development. The field is expanding into autoimmune diseases, with nononcology trials representing 51% of the pipeline by late 2024.

Pharmacy Technician 26

Pharmacy Technician Diabetes Compounding Compounding Pharmacies 26

STAT

FEBRUARY 7, 2025

Bain will acquire a centuries-old drugmaking division currently developing medicines for neurological and immune disorders, among other kinds of conditions, allowing Mitsubishi to focus on its core chemical business. billion, in one of the private equity firm’s largest life science deals.

Immunity 254

Immunity Immunization Drug Pricing Drug Development 254

Pharma Marketing Network

MAY 11, 2025

Though these companies operate on longer timelines and more complex supply chains, they arent immune. As price cuts affect the blockbuster drugs they help manufacture, their contract revenue is indirectly exposed. Even biologics manufacturers are being affected. How should Asian pharma brands respond to this trend? Absolutely.

Drug Pricing 59

Drug Pricing Biosimilars Communication Pharmaceutical Companies 59

Pharmaceutical Technology

JUNE 23, 2025

The European Commission (EC) has approved argenx’s Vyvgart (efgartigimod alfa) 1000mg as a single agent for subcutaneous injection to treat adults with chronic inflammatory demyelinating polyneuropathy (CIDP), an immune-mediated neuromuscular disorder of the peripheral nervous system.

Pharmaceutical Manufacturing 52

Pharmaceutical Manufacturing Communication Hospitals Packaging 52

BioPharma Dive

JUNE 26, 2025

Vor Biopharma licensed a drug in June 2025 that targets proteins essential to B cell survival. Love Employee via Getty Images Dive Brief: Vor Biopharma is licensing rights to an immune disease drug from Chinese biotechnology company RemeGen, it said Wednesday, a little over one month after announcing plans to review strategic alternatives.

Drug Pricing 43

Drug Pricing Immunity Immunization Drug Development 43

Pharmaceutical Technology

JUNE 23, 2025

June 23, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook HBM7020 activates immune system T cells to target and destroy B cells and plasma cells involved in many autoimmune diseases. Credit: luchschenF /Shutterstock.

Insurance Coverage and Processing 52

Insurance Coverage and Processing Communication Pharmaceutical Manufacturing Hospitals 52

PharmaVoice

JUNE 25, 2025

Few diseases have suffered more drug development disappointment than amyotrophic lateral sclerosis. Earlier this year, an experimental drug from Denali Therapeutics, and a candidate from Calico Life Sciences and AbbVie, failed in the clinic. Please let us know if you have feedback.

Packaging 262

Packaging Immunity Immunization Drug Development 262

BioPharma Dive

JUNE 27, 2025

These medicines are made from a patient’s own immune cells, extracted from the body and engineered in a lab to hunt down specific proteins found on the surface of malignant clones. But their administration also comes with notable risks, including a hyperactive immune response known as CRS and neurological toxicity dubbed ICANS.

Drug Pricing 70

Drug Pricing Hospitals Immunity Immunization 70

PharmaTech

JUNE 24, 2025

Some companies are combining mRNA vaccines with programmed cell death protein 1 (PD-1) inhibitors to activate the immune system and elicit tumour-specific T-cell responses. The LNPs provide targeted delivery of the mRNA directly to tumours, resulting in strong immune activation, tumour elimination, and durable immunological responses.

Vaccines 59

Vaccines Dosage Drug Development Immunity 59

STAT

OCTOBER 29, 2024

But many other modes of immunotherapy for cancer were approved first — checkpoint blockade drugs like Keytruda and engineered immune cell therapies like Yescarta. Cancer vaccines may also be able to help train the immune system to recognize and kill cancers related to viruses like HPV.

Vaccines 363

Vaccines Immunity Immunization Drug Development 363

PharmaTech

JUNE 26, 2025

However, the company went on to say that as many as 60% of patients treated with CAR-T cells experience “high-grade toxicities,” such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Pharmaceutical Compounding Calculations, Part Two–Bulk Drugs Paul L. million (approximately US$1.99

Dosage 59

Dosage Drug Development Vaccines Labelling 59

Pharmaceutical Technology

JUNE 20, 2025

Find out more This treatment involves obtaining immune cells from patients, modifying them in a laboratory setting then reintroducing them into patients’ bodies to destroy cancerous cells. Data Insights The gold standard of business intelligence. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate?

Insurance Coverage and Processing 52

Insurance Coverage and Processing Hospitals Communication Pharmaceutical Manufacturing 52

PharmaVoice

JUNE 13, 2025

health agencies have also added restrictions to COVID-19 shots and are considering new rules that could increase the time and cost of vaccine drug development. But the reality right now is that immunization rates are stalling and millions of infants are missing out on critical vaccinations.

Vaccines 130

Vaccines Immunity Immunization Drug Development 130

FDA Law Blog: Biosimilars

DECEMBER 15, 2024

For example, characterization testing of a cell-based product may include extended assessment of cell surface phenotypic markers, such as those associated with immune-cell activation, differentiation, and exhaustion.

Documentation 52

Documentation Immunity Immunization Drug Development 52

Pharmaceutical Technology

JULY 14, 2025

A single dose of the vaccine in adults aged 18-49 at increased risk of RSV-LRTD elicited robust immune responses that were non-inferior to those observed in adults aged 60 and above. That is instead recommended by the US Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP).

Labelling 52

Labelling Vaccines Insurance Coverage and Processing Packaging 52

Pharmaceutical Technology

JUNE 18, 2025

Reports Use of Artificial Intelligence in Pharmaceutical Drug Development a. fired 17 sitting members of the Advisory Committee on Immunization Practices at the Centers for Disease Control and Prevention (CDC), concerns rose about the stance of federal agencies on vaccines. Find out more Sign up for our daily news round-up!

Vaccines 52

Vaccines Communication Hospitals Drug Development 52

Pharmaceutical Technology

JULY 15, 2025

LaNova’s drug development focuses on tumour immunity and the tumour microenvironment. The company has particular emphasis on antibody-drug conjugates (ADCs) and has built several platforms within this modality. A timeline of 30 business days has been set by the companies to finalise the deal. by market close.

Packaging 73

Packaging Communication Hospitals Drug Development 73

STAT

JULY 7, 2025

The drug will be marketed under the brand name Ekterly. Cogent Biosciences reported results from a Phase 3 study of bezuclastinib in indolent systemic mastocytosis, the most common form of an immune system disorder that causes allergic-like skin reactions, gastrointestinal and neurological symptoms, fatigue, and generalized pain. 

Immunity 170

Immunity Immunization Drug Pricing Drug Development 170

BioPharma Dive

JUNE 11, 2025

billion buyout of Blueprint Medicines is the sector’s second-largest M&A deal this year and represents the highest value paid for an immune drug developer since April 2023. Track the deals that are happening here. Sanofi’s $9.1 Track the deals that are happening here. Sanofi’s $9.1

Drug Pricing 107

Drug Pricing Immunity Immunization Drug Development 107

PharmaVoice

JULY 2, 2025

Mark Lansdell Director of custom intelligence, Evaluate The drug, already approved in China, is a bispecific antibody that targets both PD-1 and vascular endothelial growth factor (VEGF), a protein that promotes blood vessel growth and helps shield tumors from the immune system.

Drug Development 130

Drug Development Packaging Immunity Immunization 130

Pharmaceutical Technology

JULY 15, 2025

LEO’s new asset is a monoclonal antibody that blocks the activation of the interleukin-36 (IL-36) receptor – a key signalling pathway in the immune system implicated in the pathogenesis of several autoinflammatory diseases. It has also been approved in expanded indications in GPP in certain territories.

Packaging 52

Packaging Communication Hospitals Vaccines 52

STAT

MAY 5, 2025

  The charity, the Telethon Foundation, took ownership from a small biotech of a drug that has been approved in Europe to treat an ultra-rare immune disorder called ADA-SCID. Recently, though, it added an unusual new role — as a gene therapy company of sorts.    Continue to STAT+ to read the full story…

Immunity 355

Immunity Immunization Drug Development Drug Pricing 355

Pharmaceutical Technology

JUNE 25, 2025

RFK Jr has flip-flopped between endorsing and shunning the MMR vaccine , a shot that is proven to provide strong immunity against the disease.

Vaccines 116

Vaccines Hospitals Packaging Communication 116

Pharmaceutical Technology

JUNE 25, 2025

In a controversial move on 9 June 2025, US Secretary of Health and Human Services Robert F Kennedy Jr dismissed all 17 members of the Centers for Disease Control and Prevention (CDC) Advisory Committee for Immunization Practices (ACIP) that advises the federal government on vaccine safety.

Vaccines 52

Vaccines Packaging Hospitals Communication 52

European Pharmaceutical Review

FEBRUARY 24, 2025

As a bispecific T-cell engager (BiTE) therapy, Blincyto (blinatumomab) provides a new treatment approach, helping the immune system to recognise and eliminate residual cancer cells following initial treatment. The field of myeloma is probably one of the biggest examples of successful drug development in modern times, Kowalski explained.

Immunity 52

Immunity Immunization Drug Development 52

Pharma Times

JUNE 18, 2025

The drug is being evaluated as both a monotherapy and in combination with Merck & Co’s Keytruda (pembrolizumab) for cancers such as melanoma, after demonstrating tumour regression, enhanced T-cell infiltration, and durable immune memory in preclinical studies.

Immunity 89

Immunity Immunization Drug Development 89

pharmaphorum

JULY 17, 2025

The 7th Inflammasome Therapeutics Summit is your go-to forum for drug developers, translational scientists, and immunology innovators striving to push inflammasome-targeted therapies from concept to clinic. If you are serious about leading the charge in inflammasome drug development, this is where the future takes shape.

Immunity 52

Immunity Immunization Diabetes Pharmaceutical Companies 52

STAT

JUNE 2, 2025

The Phase 1 trial, which enrolled 118 healthy volunteers, tested the safety and tolerability of KT-621, a small molecule drug that targets STAT6, a signaling protein that plays a key role in driving immune activation.

Immunity 306

Immunity Immunization Drug Development 306

STAT

MAY 27, 2025

The cause of death is still being investigated but Rocket said the patient experienced complications due to capillary leak syndrome, possibly tied to an immune-suppressing treatment used prior to the patient receiving the Rocket gene therapy, called RP-A501. The FDA placed the study on clinical hold.

Immunity 252

Immunity Immunization Drug Pricing Drug Development 252

STAT

MARCH 22, 2024

The Food and Drug Administration on Friday authorized a new antibody to protect immunocompromised individuals against Covid-19.    The drug, known as Pemgarda and marketed by the biotech Invivyd, is the first such drug to become available since the agency pulled AstraZeneca’s Evusheld off the market in January 2023.

Immunity 364

Immunity Immunization Drug Development 364

STAT

OCTOBER 14, 2024

Biotech investors have been buzzing around new areas of drug development this year, such as the red-hot obesity market. billion to companies developing treatments for conditions in which the body’s own immune system goes haywire, attacking healthy cells and tissues and causing widespread damage.

Immunity 363

Immunity Immunization Drug Development 363

STAT

MAY 22, 2024

Biogen is joining the industry’s fervor over immune and inflammatory disease drug development with a new acquisition. HI-Bio, which is based in San Francisco, is developing therapies for immune-mediated diseases like primary membranous nephropathy and IgA nephropathy, both of which impact kidney function.

Immunity 339

Immunity Immunization Drug Development 339

European Pharmaceutical Review

OCTOBER 20, 2022

Recognising the potential of CAR T cells to act as highly targeted therapeutics, several biotechnology companies – including Sangamo Therapeutics – have established development pipelines of CAR T regulatory cells (Tregs) that aim to tackle immune?mediated What are Tregs and how are they applicable to immune-mediated disease?

Immunity 140

Immunity Immunization Drug Development 140

pharmaphorum

JUNE 15, 2022

The 2nd NSCLC Drug Development Summit returns for its second year to unite biopharma and academic leaders during an exciting era of personalized medicine. Improve your drug development rationale across all lines of NSCLC and address challenges when moving therapies forward. Progress sequencing and combination approaches.

Drug Development 105

Drug Development Immunity Immunization 105

Outsourcing Pharma

DECEMBER 21, 2020

A partnership between Immunai and 10x Genomics will use artificial intelligence to create a map of the immune system to help accelerate drug development.

Immunity 96

Immunity Immunization Drug Development 96

STAT

APRIL 10, 2024

The promise has long been an affordable, personalized cancer vaccine that could train the immune system to recognize proteins from cancer cells and, subsequently, destroy the tumor.

Vaccines 364

Vaccines Immunity Immunization Drug Development 364